APA

Rajesh Y., Biswas A., Kumar U., Das S., Banerjee I., Banik P., Bharti R., Nayak S., Ghosh S. K. & Mandal M. (20200213). Targeting NFE2L2, a transcription factor upstream of MMP-2: A potential therapeutic strategy for temozolomide resistant glioblastoma. : Biochemical pharmacology.

Chicago

Rajesh Y, Biswas Angana, Kumar Utkarsh, Das Subhayan, Banerjee Indranil, Banik Payel, Bharti Rashmi, Nayak Santoshi, Ghosh Sudip K and Mandal Mahitosh. 20200213. Targeting NFE2L2, a transcription factor upstream of MMP-2: A potential therapeutic strategy for temozolomide resistant glioblastoma. : Biochemical pharmacology.

Harvard

Rajesh Y., Biswas A., Kumar U., Das S., Banerjee I., Banik P., Bharti R., Nayak S., Ghosh S. K. and Mandal M. (20200213). Targeting NFE2L2, a transcription factor upstream of MMP-2: A potential therapeutic strategy for temozolomide resistant glioblastoma. : Biochemical pharmacology.

MLA

Rajesh Y, Biswas Angana, Kumar Utkarsh, Das Subhayan, Banerjee Indranil, Banik Payel, Bharti Rashmi, Nayak Santoshi, Ghosh Sudip K and Mandal Mahitosh. Targeting NFE2L2, a transcription factor upstream of MMP-2: A potential therapeutic strategy for temozolomide resistant glioblastoma. : Biochemical pharmacology. 20200213.